Inovio COVID-19 vaccine

In February 2020 after receiving details of the genetic sequence of the coronavirus, Inovio announced that it had produced a preclinical DNA-based vaccine as a potential therapy for COVID-19.

[5][7] In early June, Inovio partnered with the International Vaccine Institute and Seoul National University, South Korea, to advance human research on INO-4800 in a Phase I-II safety and efficacy trial to be conducted on 120 participants at Seoul National University Hospital beginning in June.

The news followed recent phase I data showing '4800 performed about in line with already available competitors against the existing SARS-CoV-2 variants.

[citation needed] On 26 August 2021 Inovio's global Phase 3 efficacy trial receives authorization to proceed from Brazil.

Conclusion INO-4800 appears safe and tolerable as a primary series and as a booster with the induction of both humoral and cellular immune responses.